Switching antipsychotics: an updated review with a focus on quetiapine (Q36276541)

13 August 2017

1 reference

title

Switching antipsychotics: an updated review with a focus on quetiapine (English)

1 reference

13 August 2017

Peter J Weiden

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

4 October 2005

1 reference

Journal of Psychopharmacology

13 August 2017

published in

1 reference

13 August 2017

volume

20

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

104-118

1 reference

Consensus development conference on antipsychotic drugs and obesity and diabetes

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Effect of antipsychotic medication on speed of information processing in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Tardive akathisia: an analysis of clinical features and response to open therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Antipsychotic withdrawal symptoms: phenomenology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Depression, hopelessness and suicide in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Suicide among schizophrenics: a comparison of attempters and completed suicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Does olanzapine have antidepressant properties? A retrospective preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Aripiprazole: profile on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

The Causes of Underdiagnosing Akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Extrapyramidal side effects are unacceptable

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Review of quetiapine and its clinical applications in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Switch to quetiapine in antipsychotic agent-related hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Prolactin levels and adverse events in patients treated with risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

The effects of clozapine on tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

The dose-response relationship for memory impairment by anticholinergic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Treatment-resistant schizophrenia--the role of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Association of anticholinergic load with impairment of complex attention and memory in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

The psychological impact of psychiatric admission: some preliminary findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Trends in the Rate and Type of Antipsychotic Medications Prescribed to Persons With Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

The natural history and pathophysiology of treatment resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Effects of anticholinergic medication on memory in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Relationships between medication treatments and neuropsychological test performance in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Efficacy of newer generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Does cognitive function improve with quetiapine in comparison to haloperidol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Elevated prolactin in pediatric patients on typical and atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056668

21 January 2018

Identifiers

DOI

10.1177/0269881105056668

1 reference

13 August 2017

1 reference